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Abstract: The time of year when patients experience exacerbations of chronic obstructive 
pulmonary disease is a much-overlooked feature of the disease. The higher incidence of exac-
erbations in winter has important consequences for patients in terms of increased morbidity and 
mortality. The seasonality also imposes a considerable burden on already-overloaded health care 
services, with both primary care consultations and hospital admissions increasing in number. 
The seasonality of exacerbations varies with latitude, and is greater in more temperate climates, 
where there may be less protection from outdoor and indoor cold exposure. The precise causes 
of the seasonality are unknown, but thought to be partly due to the increased prevalence of 
respiratory viral infections circulating in cold, damp conditions. Increased susceptibility to viral 
infection may also be a mechanism mediated through increased airway inflammation or pos-
sibly reduced vitamin D levels. The seasonality of exacerbations informs us about the triggers 
of exacerbations and suggests possible strategies to reduce their number.
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Definition of COPD exacerbation
There is no simple definition of chronic obstructive pulmonary disease (COPD) exacer-
bation, due to the heterogeneity of causative microorganisms and environmental agents, 
the variety of respiratory symptoms involved, the behavior of patients with regard 
to seeking medical care, and the multiplicity of airway and systemic inflammatory 
changes. Patients typically experience acute or progressive worsening1 of one or more 
respiratory symptoms, particularly dyspnea, sputum purulence, and sputum volume. 
They may also complain of symptoms of nasal discharge, wheeze, sore throat, cough-
ing, and/or fever.2,3 Other manifestations can include fatigue, acute confusion, malaise, 
or worsening exercise tolerance.4 Airway and systemic inflammatory markers increase 
at exacerbation, though possibly not with sufficient sensitivity and specificity for one 
alone to act as a biomarker of an exacerbation.5–7 The intensity of these respiratory 
symptoms may cause some patients to self-treat or seek treatment from a physician. 
Treatment is typically with a course of antibiotics and/or oral corticosteroids. Some 
patients may be admitted to hospital. The decision to admit may depend on the frailty 
of the patient, the severity of the COPD, whether the patient is in acute respiratory 
failure, and the presence or not of comorbidities. Any decision to admit may also be 
influenced by the patient’s ability to cope at home,8 the speed of access to primary 
care,9 and on local custom and practice, as some countries are more likely to admit a 
COPD patient than others.10 In elderly COPD patients, an exacerbation might result 
in death. This complexity in exacerbation presentation has resulted in many different 
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outcomes measures being used to assess the seasonality of 
COPD exacerbations.
Exacerbation seasonality
So far, there has been only one global study of exacerbation 
seasonality. It used data collected during the 3-year TORCH 
(TOwards a Revolution in COPD Health) study, which was 
designed to investigate the components and combination of 
salmeterol and fluticasone propionate versus placebo and 
involved 6,112 patients across the globe.11 Patients were 
40–80 years old with a spirometrically confirmed diagnosis 
of COPD and a 10 pack-year smoking history. Exacerbations 
were defined as events requiring treatment with antibiotics 
and/or oral corticosteroids, or requiring hospitalization. 
The analysis of seasonality was limited to data collected 
between April 2001 and March 2005. Figure 1 shows that 
the seasonal pattern of exacerbations in the northern hemi-
sphere (n=4,849 patients) mirrored that in the southern 
hemisphere (n=622), but not in the tropics (n=641). In the 
north, 9% of patients had exacerbations between December 
and February compared to 5% in June to August. This trans-
lates into an 80% winter excess in exacerbations, whereas in 
the southern hemisphere, 12% of patients had exacerbations 
in their winter (June–August) compared to 7% in summer 
(December–February): a 71% winter excess. Therefore, apart 
from the tropics, exacerbation seasonality appears to be a 
global phenomenon.
Another, large multicenter investigation of seasonality 
used data from another randomized, controlled trial: the 
POET-COPD (Prevention Of Exacerbations with Tiotropium 
in COPD) study.12 It involved a 12-month-long follow-up of 
7,376 patients living in the northern hemisphere. Exacerba-
tions were defined as an increase in respiratory symptoms 
(dyspnea, cough, sputum, wheeze, or chest tightness) for 
3 or more days that required treatment with oral corticos-
teroids and/or antibiotics or required hospitalization and 
were separated by at least 7 days. The study was performed 
between February 2008 and April 2010. Mean monthly 
exacerbation rates during winter (December–February) 
were 7.63 per 100 patient-months compared to 3.53 per 
100 patient-months in summer (June–August): a 116% 
winter excess.
Single-center studies have made similar observations, 
albeit in smaller numbers.13 In the UK, between 1995 and 
2009, 307 COPD patients enrolled in a London COPD cohort 
recording worsening of respiratory symptoms with a paper 
diary to identify exacerbations using a symptomatic defini-
tion involving 2 consecutive days of one major respiratory 
symptom (increased dyspnea, sputum purulence, or sputum 
volume) plus another respiratory symptom that could be 
another major symptom or a minor symptom (coryzal, 
wheeze, sore throat, or cough). The patients experienced 
1,052 exacerbations in the cold season (November–February) 
compared to 676 in the warm season (May–August): an 
excess of 56.6%.14 Figure 2 shows that in this cohort of 
patients, the percentage of patients reporting respiratory 
symptoms or the exacerbation of an onset increased as tem-
peratures fall, while outdoor activity and peak expiratory 
flow rates decrease.
In Canada, a cohort of 71 COPD patients were asked to 
fax daily diary sheets to a coordinating center. The center 
identified exacerbations when symptom levels exceeded normal 
for 2 consecutive days and patients were scheduled a home visit 
by a nurse. The study detected 47 (6.7 per week) exacerbations 
during the Christmas period of (December 1 to January 17) 
compared to 63 exacerbations (4.3 per week) during January 
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during recovery from exacerbation in the winter (a fall 
of 0.5 hour/day [IQR -1.1 to 0] relative to just before the 
exacerbation started) compared to a fall of 0.26 hour/day 
(IQR -0.88 to 0.18) in summer (P=0.048).
Seasonality of hospital admission
Health services come under pressure in winter.20 This is due in 
part to increased hospital admissions for COPD exacerbations. 
The increase in admissions is observed across Europe,21 in 
Spain,22 Finland,23 Portugal,24 and the UK,25 and in the US,26 
South Korea,27 and Hong Kong.28 The phenomenon, being con-
sistent, is therefore predictable. Monthly admissions to hospital 
in Ontario, Canada over the previous year have a good correla-
tion with the number of admissions in the following 12 months 
(R2=0.71), with all predictions falling inside 95% confidence 
intervals.29 In the UK, the Meteorological Office developed a 
scheme to alert patients and health care professionals to immi-
nent cold weather and possible exacerbation of their disease.30 
Though this was successful in predicting increased hospital 
admissions, a cost–benefit analysis suggested that patients 
needed to be targeted. In particular, those patients with frequent 
exacerbations (three or more in the previous 12 months) and 
those with one or two previous admissions could be approached. 
However, they account for only 8% and 22%, respectively, of 
winter admissions, as 70% of patients admitted have no previ-
ous admission in the preceding 12 months.31
18 to April 30), which is equivalent to a 36.2% increase.15 
This figure is not however comparable to the aforementioned 
studies, where winter was compared with summer. The study 
suggested that exacerbations are more likely over Christmas, 
when social events make cross-infection easier, but this spike 
over Christmas is not seen in other countries.
Seasonality of patient-reported 
outcomes
There is very little in the literature about the seasonality of 
patient-reported outcome measures collected directly from 
the patient, usually by questionnaire, concerning COPD 
exacerbations. Exacerbation frequency is an important 
determinant of health-related quality of life (St George’s 
Respiratory Questionnaire [SGRQ] total scores),16 and 
these scores are higher in winter than spring or summer.17 
Anxiety and depression scores are also related to exacerbation 
frequency,18 and higher in winter (11.6 [6.3] and 9.3 [2.7]) 
respectively, than summer (6.5 [4.3] and 6.0 [3.8]) (P,0.001 
and P,0.02, respectively).19
The impact of exacerbations on patients also seems 
to vary between different periods of the year. Exacerba-
tions took a median of 10 days (interquartile range [IQR] 
6–19, n=892) to recover in winter (November–February) 
compared to 9 days (IQR 5–16, n=595; P=0.005) in the 
summer (May–August).14 Patients spent less time outdoors 
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Figure 2 Diary-card data collected from the London COPD cohort between November 1995 and November 2012. 
Notes: Points are the percentage of patient-reporting activity, worsening of respiratory symptoms or onset of exacerbation on days within 1°C, or average peak expiratory 
flow rate on those days.
Abbreviations: COPD, chronic obstructive pulmonary disease; PEFR, peak expiratory flow rate.
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There are differing data over the role of  socioeconomic 
factors concerning hospital admissions in winter. Jordan et al32 
found no effect of socioeconomic deprivation (Townsend 
scores) or home-heating levels on hospital admissions, but 
did observe that being housebound and receiving two or 
more courses of oral corticosteroids in the previous year 
were significant predictive factors leading to admission. This 
study was relatively small, involving patients registered at 
79 practices in central England, and relatively short, as it was 
conducted over only one winter (2003–2004). In a much-
larger study covering all COPD admissions in Scotland in 
the period 2001–2010, McAllister et al33 found a synergistic 
relationship between winter and deprivation, with a larger 
winter–summer difference of 39 compared to seven admis-
sions for COPD per 10,000  person-years between the most 
and least deprived areas of Scotland.
The length of hospital stay appears also to vary with 
season. In a study of 153,401 hospital admissions between 
1987 and 1998 across Finland, the length of stay was 
12.3 days (standard deviation 62.3) in winter and 11.0 days 
(standard deviation 42.3) in summer (P=0.001), and it was 
suggested that the light and warm northern summers serve 
to shorten hospital stays.34 Attendance at group pulmonary 
rehabilitation centers is also significantly lower in the winter, 
64% compared to 74% during summer.35
Winter pressures on primary care
There have been very few investigations into the seasonality 
of primary care consultations. In a retrospective time-series 
analysis of primary care visits for respiratory disease in 
Ontario, Canada from January 1992 to December 2002, 
there was clear seasonality in COPD consultations, with 
more in winter, matching those in other respiratory diseases 
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Figure 3 Seasonality of COPD mortality, by age.
Notes: Mean daily deaths per million population (mortality) for men and women aged 65–74, 75–84, and 85+ years for each month between 1976 and 2012 in england 
and Wales from COPD (coded with the ninth and tenth International Classification of Diseases [ICD] as ICD-9 490–492, 496 for years before 2001, and ICD-10 J40–J44 
thereafter) were extracted from death-registration data supplied by the Office of National Statistics (ONS). To be compatible with deaths before 1983 and after 1993, daily 
deaths from COPD were divided by 0.940 to adjust for differences in mortality-coding instructions in the intervening years. Deaths classified using the ICD-10 (2001–2012) 
were divided by 0.966 to allow for differences between the ICD-9 and ICD-10. Deaths per day per million population were obtained after dividing daily deaths by daily 
population estimates obtained by fitting a fifth-order polynomial to yearly estimates of the populations from the ONS from census data.
Abbreviation: COPD, chronic obstructive pulmonary disease.
such as  respiratory syncytial virus (RSV) infection and 
influenza-induced asthma.36
Seasonality of mortality  
from COPD
In England and Wales, about 15% of all deaths are from 
respiratory disease, and of these about 36% are due to COPD 
(International Classification of Diseases [ICD]-10 J40–J44).37 
In a study of the UK population’s vulnerability to winter 
mortality, seasonal variations in deaths from all causes can 
be explained almost entirely by a categorical variable for the 
month, average temperatures over the previous 13 days, and 
weekly influenza A counts from public health laboratories.38 
This implied that these three factors alone determine excess 
winter mortality. Much of the excess winter mortality was 
in people with preexisting respiratory disease. This group 
experienced a winter:nonwinter ratio in mortality of 1.20 
times greater than in people without a respiratory illness.
Deaths from COPD increase significantly during the cold 
weather experienced in winter, but this is generally men-
tioned as an adjunct to studies into the effects of atmospheric 
pollution.39,40 Few studies have specifically examined excess 
winter COPD mortality. Figure 3 shows clear seasonality in 
COPD deaths, which are consistently higher in winter and 
greater in older age-groups. An important difference between 
the effects of atmospheric pollutants and cold weather is 
that pollutants are associated with an immediate increase in 
COPD mortality,39 whereas temperature appears to have a 
delayed effect. Figure 4 shows that respiratory disease (ICD-9 
460–519) peaks 12 days after a cold day.41 This difference in the 
delay-to-peak effect can be explained. Atmospheric pollutants 
cause bronchoconstriction and increased mucus production. 
This might be sufficient to tip the balance in already-seriously 
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temperatures fell to 0°C.43,44 The surveyed Russians generally 
had higher indoor temperatures and wore more and thicker 
clothing (a fur coat, hats, and gloves). Other adaptations 
were triple-glazed windows and buildings with double and 
sometimes triple sets of doors to the outside. These mea-
sures could be adopted elsewhere to keep houses warm and 
save on fuel.
These survey studies support the reasonable assumption 
that improvements in home heating can reduce excess winter 
deaths and hospital admissions. However, a systematic review 
of housing intervention45 found no improvement with regard 
to respiratory health in nine different European studies, 
although improvements in the respiratory health of children 
were observed in two New Zealand studies.46,47 Indeed, 
another study of elderly people living in fully heated housing 
and not directly charged for its cost experienced the same 
excess winter all-cause mortality as the surrounding elderly 
population.48,49 In COPD patients, a cross-sectional study of 
148 individuals found only a weak associations (R2=0.14) 
between poorer scores in the symptom subcomponent of the 
SGRQ and fewer days with 9 hours of warmth (.21°C) in 
the living room, independent of age, lung function, smoking, 
and outdoor temperatures.50 No improvements were seen 
in activity or impact scores or total SGRQ scores, or in the 
EuroQol Visual Analogue Scale, though the trends were in 
the direction that suggested that warmth improved respira-
tory health. One possibility is that cold outdoors is the most 
important determinant of respiratory mortality and morbidity, 
probably not through a direct effect on the body, but indirectly 
by prolonging the survival of viruses in the environment.
Respiratory viruses  
and exacerbations
An important cause of COPD exacerbations is airway 
infection by a respiratory virus. Table 1 shows that the 
detection rate of respiratory viruses at exacerbation varies 
from 22%,51 37%,52 39%,53 42%,54 to 57%.55 A fairly con-
sistent finding is that the most common respiratory virus 
detected at COPD exacerbation is human rhinovirus. The 
results from Ko et al51 were detected in nasopharyngeal 
aspirates alone, while the other studies examined sputum 
and/or nasal lavage.
Seasonality of respiratory viruses
Figure 5 shows viral isolation counts from Public Health 
Agency laboratories for 1980–2008 for all ages and sexes, 
by week number. Influenza A, RSV and Mycoplasma 
pneumoniae occur mainly in the winter to early spring, 
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Figure 4 Time-series analysis showing the time courses of respiratory mortality 
following a cold day. 
Notes: M ReS describes the increase in mortality per 1°C fall in temperature. The 
y-axis is the regression coefficients of mortality on temperature on days before and 
after day 0. The horizontal line is the means of values at lag -30 to -16 days. *Peak 
value and significantly different from zero, P,0.001. Reproduced from J Epidemiol 
Community Health, early increases in ischaemic heart disease mortality dissociated 
from and later changes associated with respira tory mortality after cold weather in 
south east england, Donaldson GC, Keatinge wR, 51(6),643–648, copyright 1997, 
with permission from BMJ Publishing Group Ltd.40
Abbreviation: M ReS, respiratory disease mortality.
ill individuals, whereas cold might increase the likelihood of 
infection, which once established takes time to progress and 
cause death.
Indoor and outdoor cold exposure: 
warm housing
There are epidemiologic data to suggest that increased 
respiratory mortality in winter is due both to indoor and 
outdoor cold exposure. The Eurowinter study examined 
mortality data for 1988–1992 in eight regions across Europe 
for people aged 50–59 and 65–74 years, and related their 
increases in mortality per 1°C fall in temperature to data 
on personal cold protection collected by a survey of 1,000 
individuals of similar age and sex in each region.42 The study 
found greater cold-related respiratory mortality in warmer 
rather than colder regions of Europe. People living in warm 
regions paradoxically had colder living rooms and shivered 
more outdoors when the temperature was 7°C.42 This was 
attributed to the people in cold regions protecting themselves 
better from the cold. Subsequent studies showed that it is 
possible for a population to avoid any increase in cold-related 
respiratory mortality over the temperatures range typically 
experienced in Western European countries. In the cities 
of Yekaterinburg (western Siberia) and Yakutsk (eastern 
Siberia), there was no increase in respiratory mortality as 
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influenza B peaks in late spring, and parainfluenza in 
summer. Rhinoviruses, adenoviruses, and corona viruses 
occur throughout the year. Rhinovirus detection falls dur-
ing the summer holidays, but rises around the time that 
the new academic year starts. Data from other countries 
will differ due to local social patterns and meteorological 
conditions, with the autumnal peak in the UK possibly 
not as pronounced as that observed in the US.56,57 One 
limitation of these data is that rates cannot be determined, 
as the number of people presenting to a physician with a 
respiratory infection is unknown. Furthermore, the deci-
sion to send a sample for investigation may be influenced 
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Figure 5 weekly data on laboratory reports of respiratory virus isolation by the Health Protection Agency/Public Health england and National Health Service hospital 
laboratories in england and wales.
Notes: Data points are the average for that week over years 1980–2013. The y-axes show the number of viruses isolated per week. Adapted from Respiratory infections: 
laboratory reports 2014 [homepage on the internet]. Public Health England; 2014 [updated September 5, 2014]. Available from: https://www.gov.uk/government/publications/
respiratory-infections-laboratory-reports-2014. Accessed September 24, 2014. Contains public sector information licensed under the Open Government Licence v2.0.77
Table 1 Prevalence of respiratory viruses at COPD exacerbation
Respiratory virus McManus et al49 Seemungal et al50 Beckham et al51 Rohde et al52,† Ko et al48
exacerbations, n 136 168 194 85 262
virus-positive exacerbations (%) 50 (36.8%) 66 (39.2%) 81 (41.8%) 48 (56.5%) 58 (22.1%)
viruses detected, n 56 77 88 59 56
Human rhinovirus* 57% 50% 44% 36% 14%
Influenza A 5% 8% 16% 25% 32%
Influenza B 0 4% 2% 7% 11%
Corona 2% 9% 18% 0 21%
Parainfluenza 9% 1% 10% 10% 7%
Adenovirus 18% 1% 1% 0 2%
RSv 6% 25% 8% 22% 11%
Metapneumovirus 4% 1% 0 0 2%
Notes: *Percentages for viral types are calculated as the percentage of viruses detected; totals may therefore exceed 100%, as some samples had dual infection and/or 
rounding; †data combined for serology and polymerase chain reaction.
Abbreviations: COPD, chronic obstructive pulmonary disease; RSv, respiratory syncytial virus.
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differences in time spent indoors between summer and winter 
is possibly too small to explain the large seasonal differences 
in respiratory viral infections. Furthermore, many elderly 
people live alone, and the increased isolation from infected 
individuals would make it less likely that they would get an 
infection by cross-infection. There is evidence that COPD 
patients become more anxious when the media report on 
pandemics, as occurred in the 2009 H1N1 pandemic in 
Melbourne, Australia.65
Reducing exacerbation seasonality
One way of reducing exacerbation seasonality would be 
to reduce the incidence of respiratory virus infection by 
immunization. Vaccines against human rhinovirus have not 
been successful, as there is little cross-protection between 
serotypes. Vaccination against influenza is widely available, 
and coverage has risen since 1980 from 15% to 65%. The 
efficacy of influenza vaccination in the elderly has recently 
been challenged,66 questioned,67–69 and rebutted.70 However, 
any protection is extremely worthwhile, as the risk of death 
from respiratory and cardiovascular causes is high during 
an epidemic, with cardiovascular deaths being attributed to 
an increase in procoagulation factors, like fibrinogen, whose 
production in the liver is stimulated by the inflammatory 
marker interleukin 6.71 Hand disinfection with ethanol does 
not appear to protect much against rhinoviral infection.72 
Vitamin D supplementation has been proposed as a way 
of reducing seasonal exacerbations, as serum levels fall 
in winter due to lack of sunshine and deficiency is associ-
ated with increased infections, possibly by altering innate 
immunity.73 However, low 25-hydroxyvitamin D levels in 
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by concerns over the latest global epidemic or the age of 
the patient, as samples from young children tend to pre-
dominate. Therefore, comparisons from year to year are 
somewhat problematic.
The role of temperature in the development of  respiratory 
infection is not clear. Some studies show that a cold environment 
can lead to the development of a cold. For example, in a study 
of 892 military recruits in Finland,58 a 1°C fall in temperature 
increased the risk for an upper respiratory tract infection by 
4.3% (P,0.0001), for the common cold by 2.1% (P=0.004), 
and for sore throat by 2.8% (P=0.019). The estimated risk 
of a lower respiratory tract infection was 2.1% per 1°C fall 
(P=0.038). Similarly, in another study, 180 healthy medical 
students at Cardiff University who placed their feet in water 
at 10°C for 20 minutes reported 13 of 90 colds 4–5 days later 
compared to 5 of 90 controls (P=0.047).59 However, others have 
shown that cooling does not favor the development of a cold. 
At the Common Cold Research Unit, patients chilled at 60°F 
(15.6°C) for 4 hours dressed solely in shorts and socks or for 
2 hours in street clothes, overcoat, and hat and inoculated with 
infective secretions developed almost the same percentage of 
colds as unchilled subjects.60 A number of mechanisms have 
been proposed by which a cold environment might increase 
host susceptibility to infection. Breathing cold air might cool 
the nasal epithelium and inhibit respiratory defenses, such as 
mucociliary clearance, or reduce the phagocytic activity of 
leukocytes.61
Alternatively, a cold environment might favor the survival 
of viruses, and their longer life span facilitates transmission 
and cross-infection. Most respiratory viruses are transmit-
ted with a coating of saliva or mucus that acts as a barrier 
to the environment, either in the form of aerosol droplets or 
through direct inoculation of noses or eyes.56 Low tempera-
tures (7°C-8°C) are optimal for influenza survival.62 Tem-
peratures above 60°C for more than 1 hour are considered 
sufficient to inactivate most viruses. An environment at a 
high relative humidity (70%–90%) also favors the survival 
of non-lipid-enveloped viruses, such as rhinoviruses and 
adenoviruses, although viruses with lipid envelopes (influ-
enza, corona, RSV, parainfluenza) survive longer at a lower 
relative humidity (20%–30%).62 More recent work suggests 
that absolute humidity has greater biological significance than 
relative humidity, though the precise biological mechanisms 
are unknown.63,64
Another possibility is that people crowd together indoors, 
thus facilitating cross-infection. Figure 6 shows that the 
proportion of patients with COPD going outdoors falls in 
cold weather.14 Although an attractive hypothesis, the small 
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COPD were not associated with frequent exacerbations,73,74 
and therefore supplementation is probably unlikely to reduce 
seasonal exacerbations.
There is no published evidence that the seasonality of 
COPD exacerbations has fallen over recent years, but excess 
winter mortality from all causes and respiratory disease is 
decreasing. Data from 1977–1994 showed significant decline 
in increase in deaths per 1°C fall with and without allowance 
for influenza epidemics.75 This is thought to be due to adapta-
tion of the population rather than higher temperatures through 
global climate change.76 Falls in all-cause winter mortality 
could be due to improved fuel efficiency and housing insula-
tion, better diet, more affordable heating, and government cold-
weather payments, though the precise reasons are unknown.
Conclusion
The seasonality of COPD exacerbations is an important feature 
of COPD, and the mechanisms responsible are complex and 
interrelated. More research is always needed, but a fruitful 
area would be an investigation into the reasons for the decline 
in the UK over the last few decades in excess winter mortality 
from respiratory and other causes. If we knew why this was 
happening, then these adaptive strategies could be accelerated 
with greater confidence. The development of an effective human 
rhinovirus vaccine would be of major importance, irrespective 
of the seasonality, but difficult in view of the multiple types of 
rhinovirus circulating in the community. Further research is 
also needed concerning the best ways of persuading patients to 
help themselves. Improvements in compliance and adherence to 
medication, pulmonary rehabilitation, and smoking-cessation 
plans would be a cost-effective way of helping COPD patients. 
A specific area of research might be the use of seasonal treat-
ment regimens where less anti-inflammatory medication is 
used in the summer when the patients have fewer respiratory 
symptoms and feel better, thus reducing side effects.
In summary, the seasonality of exacerbations imposes a 
considerable burden on COPD patients in terms of mortal-
ity and morbidity, and on health care systems responsible 
for patient care. This seasonality can be reduced. Further 
research and implementation of mitigation strategies would 
help patients with COPD.
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